Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Povetacicept bioavailability and bioequivalence in healthy volunteers
NCT07010406Phase 1Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Jun 2025
- Primary completion
- Aug 2025
- Modality
- Antibody Fragments, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of povetacicept (4 arms), sponsored by Vertex Pharmaceuticals. Primary endpoints: Area Under the Concentration Versus Time Curve From the Time of Dosing to 28 Days and Maximum Observed Plasma Concentration at 30 days. Started Jun 2025; status: completed.
02
Drugs
povetacicept
Beyond the preview
Go deeper on NCT07010406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07010406.